Erythropoietin encapsulation in chitosan nanoparticles and kinetics of drug release

Current Drug Delivery

Volumn 8, Issue 2, 2011, Pages 164-171

  Bokharaei, M ^a   Margaritis, A ^a   Xenocostas, A ^b   Freeman, D J ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Chitosan; Controlled release; Drug delivery; Encapsulation; Erythropoietin; Nanoparticles; rHu EPO

Indexed keywords

CHITOSAN; NANOPARTICLE; RECOMBINANT ERYTHROPOIETIN; TRIPOLYPHOSPHATE;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; GELATION; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL;

ALGORITHMS; CHITOSAN; DRUG CARRIERS; DRUG COMPOUNDING; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HYDROGEN-ION CONCENTRATION; KINETICS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POLYPHOSPHATES; SOLUBILITY;

EID: 79551646528     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111794479862     Document Type: Article

References (24)

1. Mocini, M.; Leone, T.; Tubaro, M.; Santini, M.; Penco, M. Structural, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. Curr. Med. Chem., 2007, 14, 2278-2287.
2. Lai, P. H.; Everett, R.; Wang, F. F.; Arakawa, T.; Goldwasser, E. Structural characterization of human erythropoietin. J. Biol. Chem., 1986, 261, 3116-3121.
3. Walsh, G. Biopharmaceuticals-biochemistry and biotechnology. 2ed ed, John Wiley, USA, 2003.
4. Jelkmann, W. Erythropoietin: structure, control of production, and function. Physiol. Rev., 1992, 72, 449-489.
5. Takeuchi, M.; Inoue, N.; Strickland, T. W.; Kubota, M.; Wada, M.; Shimizu, R.; Hoshi, S.; Kozutsumi, H.; Takasaki, S.; Kobata, A. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA, 1989, 86, 7819-7822.
6. Broudy, V. C.; Tait, J. F.; Powell, J. S. Recombinant human erythropoietin: purification and analysis of carbohydrate linkage. Arch. Biochem. Biophys., 1998, 265 (2), 329-336.
7. Lin, F. K.; Suggs, S.; Lin, C. H.; Brown, J.K.; Smalling, R.; Egrie, J.C.; Chen, K.K.; Fox, G.M.; Martin, F.; Stabisky, Z. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 1985, 82 (22), 7580-7584.
8. Morlock, M.; Koll, H.; Winter, G.; Kissel, T. Microencapsulation of rh-Erythropoietin, using biodegradable poly(D,L-lactide-coglycolide): protein stability and the effects of stabilizing excipients. Eur. J. Pharma. Biopharm., 1997, 43, 29-36.
9. Pistel, k.F.; Bittner, B.; Koll, H.; Winter, G.; Kissel, T. Biodegradable recombinant human erythropoietin loaded microspheres prepared from linear and star-branched block copolymers: influence of encapsulation technique and polymer composition on particle characteristics. J. Control. Release, 1999, 59, 309-325.
10. Arcasoy, M.O. The non-hematopoietic biological effects of erythropoietin. Br. J. Haematol., 2008, 141 (1), 14-31.
11. Boogaerts, M. Pleiotropic effects of erythropoietin in neuronal and vascular systems. Curr. Med. Res. Opin., 2006, 22 (4), 15-22.
12. Burger, D.; Lei, M.; Geoghegan-Morphet, N.; Lu, X.; Xenocostas, A.; Feng, Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovas. Res., 2006, 72, 51-59.
13. Kao, R.; Xenocostas, A.; Rui, T.; Yu, P.; Huang, W.; Rose. J.; Martin, M.C.; Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model. Crit. Care, 2007, 11 (3), 58.
14. Rui, T.; Fen, Q.; Lei, M.; Peng, T.; Zhang, J.; Xu, M.; Abel, E.D.; Xenocostas, A.; Kvietys, R.P. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/ reperfusion via induction of AP-1. Cardiovas. Res., 2005, 65, 719-727.
15. Vander, M. P.; Voors, A.A.; Lipsic, E.; Van Gilst, H.W.; Van Velduisen, D.J. Erythropoietin in cardiovascular diseases, Eur. Heart J., 2004, 25, 285-291.
16. Borchard, G. Chitosans for gene delivery, Adv. Drug Deliv. Rev., 2001, 52, 145-150.
17. Guliyeva, U.; Oener, F.; Oezsoy, S.; Haziroglu, R. Chitosan microparticles containing plasmid DNA as potential oral gene delivery system. Eur. J. Pharm. Biopharm., 2006, 62, 17-25.
18. Kockisch, S.; Rees, D.G.; Young, S.A.; Tsibouklis, J.; Smart, D.J. Polymeric microspheres for drug delivery to the oral cavity: An in vitro evaluation of mucoadhesive potential. J. Pharm. Sci., 2003, 92 (8), 1614-1623.
19. Rao, B.S.; Sharma, P.C. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J. Biomed. Mat. Res., 1997, 34, 21-28.
20. Sinha, V.R.; Singla, A.K.; Wadhawan, S.; Kaushika, R.; kumria, R.; Bansal, K.; Dhawan, S. Chitosan microspheres as a potential carrier for drugs, Int. J. Pharm., 2004, 274, 1-33.
21. Imoue, N.; Takeuchi, M.; Ohashi, H.; Suzuki, T. The production of recombinant erythropoietin. Biotechnol. Ann. Rev., 1995,1, 297-314
22. Sahiner, N.; Singh, M. In situ micro/nano-hydrogel synthesis from acrylamide derivates with lecithin organogel system. Polym., 2007, 48, 2827-2834
23. Hahn, K.S.; Oh, J.E.; Miyamoto, H.; Shimobouji, T. Sustained release formulation of erythropoietin using hyaluronic acid hydrogel crosslinked by Michael addition. Int. J. Pharm., 2006, 322, 44-51.
24. Xu, Y.; Du, Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int. J. Pharma., 2003, 250, 215-226.